ACE2 and COVID-19: Early in the COVID-19 pandemic, several hypotheses were generated on whether NSAIDs could upregulate angiotensin-converting enzyme 2 (ACE-2), the essential SARS-CoV-2 viral cell entry receptor, and subsequently result in an increased risk of SARS-CoV-2 infection [33,34].